Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A drug that can alleviate the exaggerated startle responses seen in hyperekplexia - or "startle disease" - in a mouse model of the condition is discussed in a paper published online in Nature Neuroscience. These findings suggest potential therapeutic avenues for individuals with hyperekplexia.
People with hyperekplexia exhibit exaggerated startle responses to unexpected auditory or tactile stimuli, such as hands clapping or taps on shoulder. Previous studies have found that this disease can be caused by mutations in the brain receptor for the neurotransmitter glycine. Existing treatments for hyperekplexia increase the function of a different neurotransmitter, GABA, which like glycine is an inhibitory neurotransmitter and reduces activity in neurons.
Taking a different path, Li Zhang and colleagues focused specifically on drugs that affect glycine receptors. They showed that one drug, TH-CBD, could increase the function of mutated glycine receptors in neurons, and indeed could ameliorate acoustic and tactile startle responses in hyperekplexia model mice. TH-CBD is a chemically modified form of cannabidiol, a prevalent constituent of cannabis plants, which is non-psychoactive, making it a more viable therapeutic option.
While the effects of drugs like TH-CBD will have to be tested further, this work highlights the potential of therapies for hyperekplexia that target glycine receptors directly.
Article adapted by Medical News Today from original press release. Source:
Please use one of the following formats to cite this article in your essay, paper or report:
Neuroscience, Nature. "Targeting glycine receptors in hyperekplexia, startle disease." Medical News Today. MediLexicon, Intl., 6 Jan. 2014. Web.
11 Mar. 2014. <http://www.medicalnewstoday.com/releases/270756>
Neuroscience, N. (2014, January 6). "Targeting glycine receptors in hyperekplexia, startle disease." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270756.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.